Jeffrey L. Bennett

21.2k total citations · 4 hit papers
178 papers, 10.7k citations indexed

About

Jeffrey L. Bennett is a scholar working on Pathology and Forensic Medicine, Neurology and Immunology. According to data from OpenAlex, Jeffrey L. Bennett has authored 178 papers receiving a total of 10.7k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Pathology and Forensic Medicine, 96 papers in Neurology and 55 papers in Immunology. Recurrent topics in Jeffrey L. Bennett's work include Multiple Sclerosis Research Studies (115 papers), Peripheral Neuropathies and Disorders (78 papers) and T-cell and B-cell Immunology (26 papers). Jeffrey L. Bennett is often cited by papers focused on Multiple Sclerosis Research Studies (115 papers), Peripheral Neuropathies and Disorders (78 papers) and T-cell and B-cell Immunology (26 papers). Jeffrey L. Bennett collaborates with scholars based in United States, Germany and United Kingdom. Jeffrey L. Bennett's co-authors include A. S. Verkman, Gregory P. Owens, Brian G. Weinshenker, Patrick Waters, Benjamin Greenberg, Kazuo Fujihara, Anthony Traboulsee, J. de Sèze, Sven Jarius and Michael Levy and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Jeffrey L. Bennett

171 papers receiving 10.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

2015 3.0k citations Dean M. Wingerchuk, Brenda Banwell et al. Neurology profile →
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

2020 317 citations Anthony Traboulsee, Benjamin Greenberg et al. profile →
Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment

2022 95 citations Jeffrey L. Bennett, John J. Chen et al. profile →
Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder

2023 82 citations Sean J. Pittock, Michael Barnett et al. Annals of Neurology profile →

Peers

Countries citing papers authored by Jeffrey L. Bennett

Since Specialization

Citations

This map shows the geographic impact of Jeffrey L. Bennett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey L. Bennett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey L. Bennett more than expected).

Fields of papers citing papers by Jeffrey L. Bennett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey L. Bennett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey L. Bennett. The network helps show where Jeffrey L. Bennett may publish in the future.

Co-authorship network of co-authors of Jeffrey L. Bennett

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey L. Bennett. A scholar is included among the top collaborators of Jeffrey L. Bennett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey L. Bennett. Jeffrey L. Bennett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study 2025 ·Neurology Neuroimmunology & Neuroinflammation ·Jeffrey L. Bennett, Kazuo Fujihara, Albert Saiz, Anthony Traboulsee, Benjamin Greenberg, Brian G. Weinshenker, Francesco Patti, Ingo Kleiter, Jacqueline Palace, J. de Sèze, Rachael A Evans, Kathleen Blondeau, Gaëlle Klingelschmitt, (unknown), (unknown), Takashi Yamamura	1
2	Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study 2025 ·Neurology Neuroimmunology & Neuroinflammation ·Jeffrey L. Bennett, Kazuo Fujihara, Albert Saiz, Anthony Traboulsee, Benjamin Greenberg, Brian G. Weinshenker, Francesco Patti, Ingo Kleiter, Jacqueline Palace, J. de Sèze, Rachael A Evans, Kathleen Blondeau, Gaëlle Klingelschmitt, (unknown), (unknown), Takashi Yamamura	1
3	Structural basis of aquaporin-4 autoantibody binding in neuromyelitis optica 2025 ·Science Advances ·Meghna Gupta, Nitesh Khandelwal, Andrew Nelson, (unknown), Sergei Pourmal, Jeffrey L. Bennett, Robert M. Stroud	3
4	B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity 2024 ·Annals of Clinical and Translational Neurology ·Jeffrey L. Bennett, Sean J. Pittock, Friedemann Paul, Ho Jin Kim, Sarosh R. Irani, (unknown), Kristina R. Patterson, Michael A. Smith, Michele Gunsior, Nanette Mittereder, William A. Rees, Daniel Cimbora, Bruce Cree	4
5	A Noncanonical CD56dimCD16dim/− NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases 2024 ·The Journal of Immunology ·(unknown), (unknown), (unknown), Inessa Cohen, Jeffrey L. Bennett, Richard J. Nowak, Elias S. Sotirchos, Erin E. Longbrake, Emily M. Mace, Kevin C. O’Connor	2
6	Patterns of clinical and imaging presentations in patients with spontaneous intracranial hypotension due to spinal cerebrospinal fluid venous fistula: A single‐center retrospective cross‐sectional study 2024 ·Headache The Journal of Head and Face Pain ·Andrew L. Callen, Lichy Han, (unknown), (unknown), Peter Lennarson, Marius Birlea, (unknown), (unknown), (unknown), Jeffrey L. Bennett, Ian Carroll	3
7	Alterations in Aquaporin‐4‐IgG Serostatus in 986 Patients: A Laboratory‐Based Longitudinal Analysis 2023 ·Annals of Neurology ·Masoud Majed, Cristina Valencia-Sánchez, Jeffrey L. Bennett, James P. Fryer, (unknown), (unknown), Andrew McKeon, John R. Mills, Dean M. Wingerchuk, Vanda A. Lennon, Brian G. Weinshenker, John J. Chen, Eoin P. Flanagan, Sean J. Pittock, Amy Kunchok	15
8	Modelling MOG antibody-associated disorder and neuromyelitis optica spectrum disorder in animal models: Spinal cord manifestations 2023 ·Multiple Sclerosis and Related Disorders ·(unknown), (unknown), (unknown), (unknown), Christopher Linington, Andrew Chan, Jeffrey L. Bennett, Robert Hoepner, Volker Enzmann, Anke Salmen	4
9	Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial (S5.002) 2023 ·Neurology ·Sean J. Pittock, Michael Barnett, Jeffrey L. Bennett, Achim Berthele, J. de Sèze, Michaël Levy, Ichiro Nakashima, (unknown), Jacqueline Palace, Friedemann Paul, Carlo Pozzilli, Kerstin Allen, (unknown), Marcus Yountz, Jung Bin Kim	1
10	Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models 2023 ·Neurology Neuroimmunology & Neuroinflammation ·(unknown), (unknown), (unknown), (unknown), Robert Hoepner, Christopher Linington, Andrew Chan, Jeffrey L. Bennett, Volker Enzmann, Anke Salmen	7
11	Heterogeneity of Acetylcholine Receptor Autoantibody–Mediated Complement Activity in Patients With Myasthenia Gravis 2022 ·Neurology Neuroimmunology & Neuroinflammation ·Abeer Obaid, Chrysoula Zografou, Douangsone D. Vadysirisack, (unknown), Miriam L. Fichtner, Bhaskar Roy, William M. Philbrick, Jeffrey L. Bennett, Richard J. Nowak, Kevin C. O’Connor	37
12	In utero exposure to maternal anti–aquaporin-4 antibodies alters brain vasculature and neural dynamics in male mouse offspring 2022 ·Science Translational Medicine ·Simone Mader, Lior Brimberg, An Vo, (unknown), James M. Crawford, Alexandre Bonnin, (unknown), (unknown), Tomás Huerta, (unknown), RoseAnn Berlin, Stephen L. Dewey, (unknown), David Eidelberg, Irena Dujmović, Jelena Drulović, Jeffrey L. Bennett, Bruce T. Volpe, Patricio T. Huerta, Betty Diamond	10
13	SAkuraBONSAI: A Prospective, Open-label Study of Satralizumab Investigating Novel Imaging, Biomarker, and Clinical Outcomes in Patients with Aquaporin-4-IgG-seropositive (P15.AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) (P15-1.002) 2022 ·Neurology ·Anthony Traboulsee, Kazuo Fujihara, Jung Bin Kim, Romain Marignier, Kevin C. O’Connor, Robert C. Sergott, Heinz Wiendl, (unknown), Scott S. Zamvil, Sean J. Pittock, Veronica G. Anania, (unknown), (unknown), (unknown), Jeffrey L. Bennett	1
14	Efficacy and safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD): Results from open-label extension periods of SAkuraSky and SAkuraStar 2021 ·Investigative Ophthalmology & Visual Science ·Zdenka Hašková, Benjamin Greenberg, Jeffrey L. Bennett, Brian G. Weinshenker, Anthony Traboulsee, Michael R. Yeaman, Kristina Weber, Kathleen Blondeau, H.‐Christian von Büdingen, Daniela Stokmaier, Gaëlle Klingelschmitt	1
15	A Longitudinal, Observational Analysis of Neuronal Injury Biomarkers in a Case Report of a Patient With Paraneoplastic Anti-CRMP5 Antibody-Associated Transverse Myelitis 2021 ·Frontiers in Neurology ·(unknown), Jeffrey L. Bennett, Gregory P. Owens, Timothy R. Vollmer, Amanda L. Piquet	4
16	Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production 2019 ·Brain ·(unknown), Panos Stathopoulos, (unknown), Alanna Ritchie, John Soltys, (unknown), (unknown), Joel Sng, Ruoyi Jiang, (unknown), Jason A. Vander Heiden, Steven H. Kleinstein, Michael Levy, Jeffrey L. Bennett, Eric Meffre, Kevin C. O’Connor	74
17	Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica 2017 ·Science Translational Medicine ·Fumitaka Shimizu, K Schaller, Gregory P. Owens, Anne C. Cotleur, (unknown), Yukio Takeshita, Birgit Obermeier, Thomas J. Kryzer, Yasuteru Sano, Takashi Kanda, Vanda A. Lennon, Richard M. Ransohoff, Jeffrey L. Bennett	91
18	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders breakdown → 2015 ·Neurology ·Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William M. Carroll, Tanuja Chitnis, J. de Sèze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Aurélio Lana–Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony Traboulsee, Patrick Waters, Kay E. Wellik, Brian G. Weinshenker	2985
19	Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis 2011 ·Journal of Neuroimmunology ·Kathryn M. Brennan, (unknown), Simon Rinaldi, Colin O’Leary, Carl S. Goodyear, Gabriela Kalna, Ariel Arthur, (unknown), Sue Barnett, Christopher Linington, Jeffrey L. Bennett, Gregory P. Owens, Hugh J. Willison	63
20	VH4 Gene Segments Dominate the Intrathecal Humoral Immune Response in Multiple Sclerosis 2007 ·The Journal of Immunology ·Gregory P. Owens, Kimberly M. Winges, Alanna Ritchie, (unknown), Mark P. Burgoon, (unknown), Kirsten Nielsen, John R. Corboy, Donald H. Gilden, Jeffrey L. Bennett	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact